CAVI-T receives CE marking to treat intranasal bleedingApril 4, 2020
Dianosic has obtained CE marking for CAVI-T, a low-pressure asymmetric balloon for treating spontaneous and post-operative intranasal bleeding.
CAVI-T, which is designed to treat intranasal bleeding (epistaxis), is patented in France.
According to the company, it is the first asymmetric intranasal balloon that stops bleeding by applying low-force compression while adapting to the anatomy of the nasal fossa. The balloon can remain in place for one to three days.
The balloon was effective in stopping bleeding in 90% of patients and significantly improved their quality of life, a pilot study found.
This feasibility study also demonstrated a good safety profile of CAVI-T, with a mean pain score on product insertion and removal of 4.7 and 1.6 respectively.